Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Authors
Keywords
-
Journal
Lancet Diabetes & Endocrinology
Volume 9, Issue 10, Pages 653-662
Publisher
Elsevier BV
Online
2021-08-21
DOI
10.1016/s2213-8587(21)00203-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
- (2020) Besmir Nreu et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
- (2020) Tali Cukierman-Yaffe et al. LANCET NEUROLOGY
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
- (2020) Juliana C N Chan et al. LANCET
- Interventions to improve oral vaccine performance: a systematic review and meta-analysis
- (2019) James A Church et al. LANCET INFECTIOUS DISEASES
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis
- (2019) Eberhard Standl Lancet Diabetes & Endocrinology
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- A review on the effects of new anti-diabetic drugs on platelet function
- (2019) Habib Yaribeygi et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Future glucose-lowering drugs for type 2 diabetes
- (2016) Clifford J Bailey et al. Lancet Diabetes & Endocrinology
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now